Molnupiravir (or MONEYpiravir): Merck pill used to combat Covid-19 failed to demonstrate it can lower the risk of hospitalization compared with a placebo among adults at a higher risk from the disease

SOURCE:https://www.statnews.com/pharmalot/2022/10/07/covid19-merck-molnupiravir-fda-mhra-hospitalization/ Substack Alexander COVID News evidence-based medicine is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.